We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+0.15%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$474M
AUM Growth
+$427M
(+909%)
Cap. Flow
+$433M
Cap. Flow
% of AUM
91.18%
Top 10 Holdings %
Top 10 Hldgs %
10.55%
Holding
454
New
296
Increased
64
Reduced
55
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
OXLC
Oxford Lane Capital
OXLC
|
+$6.86M |
| 2 |
Barings BDC
BBDC
|
+$6.33M |
| 3 |
Oxford Square Capital
OXSQ
|
+$5.45M |
| 4 |
ECC
Eagle Point Credit Company
ECC
|
+$5.29M |
| 5 |
FS KKR Capital
FSK
|
+$5.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$2.25M |
| 2 |
ACOR
Acorda Therapeutics
ACOR
|
+$644K |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
+$605K |
| 4 |
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
|
+$603K |
| 5 |
uniQure
QURE
|
+$374K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 23.58% |
| 2 | Real Estate | 14.99% |
| 3 | Energy | 13.55% |
| 4 | Healthcare | 12.23% |
| 5 | Materials | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Gossamer Bio
GOSS
$66.5M
| $292K | 0.06% |
+13,168
| New | +$252K |
|
|
IMGN
227
DELISTED
Immunogen Inc
IMGN
| $292K | 0.06% |
134,704
+84,659
| +169% | +$200K |
|
|
MRTX
228
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $292K | 0.06% |
2,839
-3,667
| -56% | -$285K |
|
|
XLRN
229
DELISTED
Acceleron Pharma
XLRN
| $291K | 0.06% |
7,095
+1,285
| +22% | +$53.2K |
|
|
UBX
230
DELISTED
Unity Biotechnology
UBX
| $290K | 0.06% |
3,055
+1,402
| +85% | +$119K |
|
|
MYOK
231
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $290K | 0.06% |
5,791
+932
| +19% | +$45.4K |
|
|
BLUE
232
DELISTED
bluebird bio
BLUE
| $289K | 0.06% |
176
-27
| -13% | -$46.7K |
|
233
CytomX Therapeutics
CTMX
$705M
| $288K | 0.06% |
25,654
+7,569
| +42% | +$79.4K |
|
234
Madrigal Pharmaceuticals
MDGL
$12.6B
| $288K | 0.06% |
+2,744
| New | +$294K |
|
|
EPZM
235
DELISTED
Epizyme, Inc
EPZM
| $288K | 0.06% |
22,930
-22,532
| -50% | -$290K |
|
236
Insmed
INSM
$23.2B
| $287K | 0.06% |
+11,200
| New | +$312K |
|
|
237
uniQure
QURE
$2.68B
| $287K | 0.06% |
3,670
-5,873
| -62% | -$374K |
|
|
DRNA
238
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $285K | 0.06% |
+18,068
| New | +$246K |
|
|
CBIO
239
Crescent Biopharma
CBIO
$602M
| $284K | 0.06% |
238
-28
| -11% | -$33.5K |
|
240
Regenxbio
RGNX
$623M
| $284K | 0.06% |
5,524
-317
| -5% | -$15.8K |
|
|
ARNA
241
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $284K | 0.06% |
+4,838
| New | +$250K |
|
242
Arvinas
ARVN
$518M
| $283K | 0.06% |
+12,884
| New | +$271K |
|
243
Kura Oncology
KURA
$922M
| $282K | 0.06% |
14,322
-5,119
| -26% | -$85K |
|
244
Viking Therapeutics
VKTX
$4.04B
| $282K | 0.06% |
33,941
+5,087
| +18% | +$43.5K |
|
|
ONC
245
BeOne Medicines Ltd
ONC
$33.8B
| $282K | 0.06% |
2,275
+234
| +11% | +$29.7K |
|
|
THOR
246
DELISTED
Synthorx, Inc. Common Stock
THOR
| $282K | 0.06% |
+20,909
| New | +$335K |
|
|
DCPH
247
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $281K | 0.06% |
12,449
+1,871
| +18% | +$43.8K |
|
248
Karyopharm Therapeutics
KPTI
$168M
| $280K | 0.06% |
3,114
+1,288
| +71% | +$103K |
|
|
AUTL
249
Autolus Therapeutics
AUTL
$386M
| $279K | 0.06% |
17,311
+8,877
| +105% | +$199K |
|
|
MYOV
250
DELISTED
Myovant Sciences Ltd.
MYOV
| $279K | 0.06% |
+30,799
| New | +$459K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2019 Portfolio in Review
As of Q2 2019, Virtus ETF Advisers held 454 positions worth $474M, up 909% from $47M the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Virtus ETF Advisers deployed $433M of net new capital in Q2 2019, opening 296 new positions and adding to 64 existing holdings. Its largest new stake was Oxford Lane Capital: 132,284 shares worth $6.67M.
By sector, the portfolio is most concentrated in Financials at 24% of assets, up from 0.73% a quarter earlier, followed by Real Estate and Energy.
On the sell side, the largest reduction was Array Biopharma Inc, an estimated $605K trimmed.
- Virtus ETF Advisers's largest Q2 2019 buy was Oxford Lane Capital: 132,284 shares worth $6.67M.
- Virtus ETF Advisers added most to Dominion Energy in Q2 2019, an estimated $2.63M increase.
- Virtus ETF Advisers's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $605K.
- Virtus ETF Advisers fully exited Spark Therapeutics, Inc. Common Stock in Q2 2019, selling an estimated $2.25M.
- Virtus ETF Advisers's ten largest holdings make up 11% of its $474M portfolio in Q2 2019.
- Virtus ETF Advisers opened 296 new positions and closed 20 in Q2 2019.
- Virtus ETF Advisers's portfolio value rose 909% quarter-over-quarter to $474M.
Based on Virtus ETF Advisers's 13F filing for Q2 2019, filed 13 Aug 2019.